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The determination of intact parathyroid hormone levels is
used for diagnosis and in the management of renal
osteodystrophy. Pre-analytical and analytical conditions are
important in the overall confidence of the assay.
Unfortunately, there are no clear recommendations for the
use of serum samples or samples anticoagulated with
ethylenediaminotetraacetic acid (EDTA) for the best
preservation of intact parathyroid hormone. In our study, the
Roche Elecsys assay was used to measure intact hormone in
both serum and EDTA plasmas from 16 hemodialysis patients
over the span of a month. Parathyroid hormone stability was
determined in samples kept frozen for 1–5 days or after
8–24 h at room temperature. There was no difference in
hormone stability between serum and EDTA samples after
1 day in frozen storage. After 5 days frozen, hormone
degradation was significantly greater after EDTA
anticoagulation than in serum aliquots. When samples were
stored at room temperature, intact parathyroid hormone was
significantly more stable in EDTA-treated samples than in
clotted serum samples, especially after 24 h. We conclude
that optimum results are achieved in the measurement of
intact parathyroid hormone levels depending on the
workflow of the lab. If the lab works with intermittent
batches of samples, frozen serum is the best. If the lab
services general practitioners and/or several hospitals and
has a continuous flow of samples, EDTA-treated samples
stored at room temperature are the best.
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In our University hospital, a high percentage of parathor-
mone (PTH) determinations realized in the laboratory are
performed in hemodialyzed patients for diagnosis and
management of renal osteodystrophy. Thus, analytical and
preanalytical conditions are of importance for a good follow-
up of the patients. Several authors have studied the stability
of PTH in serum and ethylenediaminotetraacetic acid
(EDTA) tubes, but mainly on the Immulite 2000 platform.1–4
It has been recently shown5 that the Roche Elecsys PTH
results were the most in accordance with Allegro PTH, even if
the antibodies used in these two tests are targeted against
different parts of the peptide.6 As the Kidney Disease
Outcomes Quality Initiative guidelines7 have been established
with the no more available Allegro kit, it may be important to
evaluate analytical and preanalytical influences on Roche
Elecsys PTH determination (Roche Diagnostics, Mannheim,
Germany). Our approach has been designed to be as close as
possible to the hospital real life.
Two series of blood samples were collected in an interval
of a month from 16 hemodialyzed patients at 0800 hours
immediately before commencing renal dialysis. All the
samples were drawn into 5-ml EDTA and gel separator with
clot activator tubes purchased from Becton-Dickinson
(Erembodegem, Belgium). In all cases, the tubes were filled
completely and brought to the laboratory within 30 min. On
the first set of samples, drawn in October, we evaluated the
stability of PTH when stored frozen as serum or EDTA
plasma at 201C. The stability of the ‘frozen’ PTH was
evaluated after 24 h and 5 days. On the second set of samples,
drawn in December, we investigated the stability of PTH
when conserved in the sample tube as EDTA whole blood or
clotted blood at room temperature (211C). The stability of
‘temperate’ PTH was evaluated at 0, 8, and 24 h. For both
series, the reference was the level of the corresponding tube
assayed directly after centrifugation at 41C.
In our hands, the coefficients of variation obtained with
the Roche Elecsys PTH were o5%.
Data were analyzed with the Student test for independent
samples, Kruskal–Wallis test and Zerbe method for paired
series
Considering the two groups of patients as independent
samples, the results obtained on the tubes assayed directly
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after sampling (zero time) did differ neither between October
and December nor between EDTA and serum sample tubes
(Table 1). The mean percentages of PTH degradation under
our experimental conditions are illustrated in Figure 1. Our
results have showed that there was no significant difference in
PTH degradation between serum and EDTA after 1-day
conservation at 201C (6.2 and 6.6%, respectively).
Nevertheless, when samples were kept frozen for 5 days, PTH
degradation was more important in EDTA aliquots than in
serum aliquots (10.872.4 vs 7.272.2%, P¼ 0.0004). On
the other hand, when samples were conserved at room
temperature, PTH in EDTA whole blood remained relatively
stable (mean loss of activity: 4.1%), whereas its degrada-
tion in clotted serum was already important after 8 h
(8.474.8%) and even more after 24 h (20.5710.1%).
This difference in stability between serum and EDTA tubes
was very significant (Po0.0001).
Clinically, by applying the criterion of the Royal
Australasian College of Pathologists Quality Assurance
Program, 33% of serum samples stored at room temperature
failed assurance criteria (o25% difference between the
sample and the target) and would have thus lead to a
diagnostic misclassification. In frozen series and EDTA kept
at room temperature, no transgression of this quality
criterion was observed.
As previously said, our approach was designed to be as
closed as possible as the ‘real life’ of a sample tube in a
hospital. The samples drawn in October mimicked the
different options usually faced by a laboratory: immediate
assay after reception or freezing of the samples for a further
determination, usually 24 h to 5 days after reception. The
goal of the study on the samples drawn in December was to
see what happens if the tubes are left at room temperature
from 8 to 24 h before arriving in the laboratory. This kind of
‘pragmatic’ methodology is original. Indeed, reports on PTH
stability in serum and plasma are sometimes contradictory.
This variability is linked to the great differences in the
methodologies used. For instance, the definition of the ‘zero-
point’ is, for some authors, a freshly frozen aliquot,3,8,9
whereas others consider the sample centrifuged and assayed
within 3 h.1,2,4 Moreover, conservation time at 201C before
analysis is not mentioned, which could let suppose that this
parameter is of minor or no importance.
The definition of the term ‘stability’ is not also well
defined, as most of the authors let degrade PTH in serum or
plasma EDTA and not in whole EDTA blood or clotted
serum. The conclusions of these studies are then only
applicable to sample management in laboratories and cannot
be extrapolated to pre-analytical handling of the tubes in the
wards.
From a strict point of view, it may be difficult to draw
conclusions from these studies.
Nevertheless, we agree that EDTA tubes are preferable in
situations where rapid delivery of blood to the laboratory
cannot be achieved.9 We have also observed that if PTH was
considerably more stable in EDTA than serum when left at
room temperature, it was not completely stable.3
The in vitro observation that PTH decline is observed in
serum and not in EDTA plasma suggests that the increased
protease activity may be due to the clotting process. Some
authors showed that the addition of aprotinin significantly
reduced the decline in PTH at 24 h – even if there was still a
difference with EDTA samples.10 Others found that an
addition of two protease inhibitors (aprotinin and leupeptin)
eliminated completely the decline of PTH.11
We did not find any difference between serum and EDTA
plasma at baseline, whereas some authors reported significant
higher values for EDTA plasma.2–4 Teal et al.8 did not either
find differences when they compared PTH stability in serum
and EDTA plasma with a third-generation PTH kit. They
made the hypothesis that amino-PTH, a phosphorylated
N-terminal fragment detected by third-generation immuno-
assays but not second-generation,6 could be more stable than
Table 1 | Values obtained directly after sampling in the two series of samples, drawn in October and December on EDTA or
serum tubes
Series Sample tubes Mean (pg/ml) s.d. (pg/ml) Minimum (pg/ml) Maximum (pg/ml) 95% CI for the mean s.e.m. (pg/ml)
October EDTA 330 271 19 929 168–478 72
Serum 315 261 15 895 160–458 69
December EDTA 332 269 12 1020 183–481 69
Serum 317 252 7 934 177–457 65
CI, confidence interval; EDTA, ethylenediaminotetraacetic acid.
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Figure 1 | Mean PTH variations (%) when samples are conserved
at room temperature as whole EDTA blood and clotted serum
for 8 and 24 h, or frozen aliquots of EDTA plasma and serum for
1 and 5 days.
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PTH itself. As Roche Elecsys PTH antibodies also recognize
amino-PTH, our findings reinforce this hypothesis.
When we compared the stability of PTH after 24 h in the
‘frozen’ EDTA tube with the ‘temperate’ EDTA tube, we
observed that PTH was more stable in EDTA whole blood
than in EDTA plasma conserved at 201C. This astonishing
observation might be attributable to a greater PTH sensitivity
to freezing/unfreezing than to PTH degradation by plasmatic
metalloproteases. However, a study on PTH stability after
four cycles of freezing/unfreezing did not support this
hypothesis (data not shown).
We have shown here that PTH is not always more stable in
EDTA than in serum. Indeed, EDTA is preferable when
samples are left in a ward or in a practitioner’s office at room
temperature, but once the sample is treated in the laboratory
and kept frozen, PTH is more stable in serum than EDTA,
compared with a ‘fresh’ determination. Our findings are
experimental. We do not know why we observed this
difference. On the other hand, the greater degradation of
PTH observed in serum compared with EDTA plasma still
remains unexplained.10 Our study was designed to be as close
as possible to the routine PTH determination in a laboratory.
However, in the light of our results, it could be interesting for
research purposes to perform such a study to evaluate PTH
stability after 1 year of conservation at 201C or the stability
at 801C.
In conclusion, the type of samples used for PTH
determination should depend on the way laboratories work.
On one hand, if a lab has a practice of general practitioners or
works for a multisites hospital, EDTA tubes conserved at
room temperature are better. EDTA tubes are also preferable
if a lab works in continuous flow. On the other hand, if a lab
works in batches with automates, as it used to be with
immunoradiometric assay series, and keep samples frozen
before determination, serum tubes are the best choice.
ACKNOWLEDGMENTS
We thank Drs Nadine Cielniaszek and Jackie Moreaux for providing us
with BD tubes as well as Mrs Miche`le Focant and Marie-Antoinette
Graceffa for their collaboration.
REFERENCES
1. Glendenning P, Laffer LL, Weber HK et al. Parathyroid hormone is more
stable in EDTA plasma than in serum. Clin Chem 2002; 48: 766–767.
2. Holmes DT, Levin A, Forer B, Rosenberg F. Preanalytical influences on DPC
IMMULITE 2000 intact PTH assays of plasma and serum from dialysis
patients. Clin Chem 2005; 51: 915–917.
3. Omar H, Chamberlin A, Walker V, Wood PJ. Immulite 2000 parathyroid
hormone assay: stability of parathyroid hormone in EDTA blood kept at
room temperature for 48 h. Ann Clin Biochem 2001; 38: 561–563.
4. Scharnhorst V, Valkenburg J, Vosters C, Vader H. Influence of preanalytical
factors on the immulite intact parathyroid hormone assay. Clin Chem
2004; 50: 974–975.
5. Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in
PTH measurement: implication for the care of CKD patients. Kidney Int
2006; 70: 345–350.
6. D’Amour P, Brossard JH, Rakel A et al. Evidence that the amino-terminal
composition of non-(1–84) parathyroid hormone fragments starts before
position 19. Clin Chem 2005; 51: 169–176.
7. K/DOQI clinical practice guidelines for bone metabolism and disease in
chronic kidney disease. Am J Kidney Dis 2003; 42: S1–201.
8. Teal TK, Wood JL, Stevens PE, Lamb EJ. Stability of Bio-Intact (1–84)
parathyroid hormone ex vivo in serum and EDTA plasma from
hemodialysis patients. Clin Chem 2004; 50: 1713–1714.
9. Walker KS, Seth J. Stability of parathyroid hormone in blood from
renal patients on haemodialysis. Ann Clin Biochem 2000; 37(Part 6):
800–801.
10. Anderson NR, Nicholas J, Holland MR, Gama R. Effect of a protease
inhibitor on in vitro stability of intact parathyroid hormone. Ann Clin
Biochem 2003; 40: 188–190.
11. Levin GE, Nisbet JA. Stability of parathyroid hormone-related protein and
parathyroid hormone at room temperature. Ann Clin Biochem 1994;
31(Part 5): 497–500.
372 Kidney International (2007) 72, 370–372
t e c h n i c a l n o t e s E Cavalier et al.: PTH stability: a pragmatic study
